
Switching Between Anti-CGRP Monoclonal Antibodies Reduces Headache Days in Non-Responders
A recently published retrospective study conducted at a tertiary headache center showed that switching between monoclonal antibodies (mAbs) targeting calcitonin gene–related peptide (CGRP) or its receptor significantly reduced monthly headache days (MHDs) …